25 January 2018 EMA/PRAC/8436/2018 Pharmacovigilance Risk Assessment Committee (PRAC)

New product information wording – Extracts from PRAC recommendations on signals Adopted at the 8-11 January 2018 PRAC

The product information wording in this document is extracted from the document entitled ‘PRAC recommendations on signals’ which contains the whole text of the PRAC recommendations for product information update, as well as some general guidance on the handling of signals. It can be found here (in English only). New text to be added to the product information is underlined. Current text to be deleted is struck through.

1. Dulaglutide – Gastrointestinal stenosis and obstruction (EPITT no 18931) Summary of product characteristics 4.8. Undesirable effects Gastrointestinal disorders Frequency ‘not known’: Non-mechanical intestinal obstruction

Package leaflet 4. Possible side effects Frequency ‘not known’ Bowel obstruction - a severe form of constipation with additional symptoms such as stomach ache, bloating or vomiting

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5525 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

2. Methotrexate – Pulmonary alveolar haemorrhage (EPITT no 18850) 2.1. For methotrexate-containing medicinal products with non-oncologic indications Summary of product characteristics 4.4. Special warnings and precautions for use Assessment of respiratory system Questioning the patient with regard to possible pulmonary dysfunctions, if necessary lung function test. Acute or chronic interstitial pneumonitis, often associated with blood eosinophilia, may occur and deaths have been reported. Symptoms typically include dyspnoea, cough (especially a dry nonproductive cough), thoracic pain and fever for which patients should be monitored at each follow-up visit. Patients should be informed of the risk of pneumonitis and advised to contact their doctor immediately should they develop persistent cough or dyspnoea. In addition, pulmonary alveolar haemorrhage has been reported with methotrexate used in rheumatologic and related indications. This event may also be associated with vasculitis and other comorbidities. Prompt investigations should be considered when pulmonary alveolar haemorrhage is suspected to confirm the diagnosis.

4.8. Undesirable effects Respiratory, thoracic and mediastinal disorders Not known: Epistaxis, Pulmonary alveolar haemorrhage

Package leaflet 2. What you need to know before you take [MTX] Warnings and precautions Acute bleeding from the lungs in patients with underlying rheumatologic disease has been reported with methotrexate. If you experience symptoms of spitting or coughing up blood you should contact your doctor immediately. 4. Possible side effects Serious side effects If you develop any of the following side effects, contact your doctor immediately: - inflammation of the lungs (symptoms may be general illness, dry, irritating cough, shortness of breath, breathlessness at rest, chest pain, or fever) - spitting or coughing blood

The following side effects have also been reported: Frequency not known (cannot be estimated from the available data): bleeding from the lungs

New product information wording – Extracts from PRAC recommendations on signals EMA/PRAC/8436/2018

Page 2/5

2.2. For methotrexate-containing medicinal products with oncologic indications Summary of product characteristics 4.4. Special warnings and precautions for use Respiratory system Acute or chronic interstitial pneumonitis, often associated with blood eosinophilia, may occur and deaths have been reported. Symptoms typically include dyspnoea, cough (especially a dry nonproductive cough), thoracic pain and fever for which patients should be monitored at each follow-up visit. Patients should be informed of the risk of pneumonitis and advised to contact their doctor immediately should they develop persistent cough or dyspnoea. In addition, pulmonary alveolar haemorrhage has been reported with methotrexate used in rheumatologic and related indications. This event may also be associated with vasculitis and other comorbidities. Prompt investigations should be considered when pulmonary alveolar haemorrhage is suspected to confirm the diagnosis.

Package leaflet 2. What you need to know before you take [MTX] Warnings and precautions Acute bleeding from the lungs in patients with underlying rheumatologic disease has been reported with methotrexate.

2.3. For methotrexate-containing medicinal products with both nononcologic and oncologic indications Summary of product characteristics 4.4. Special warnings and precautions for use Respiratory system Acute or chronic interstitial pneumonitis, often associated with blood eosinophilia, may occur and deaths have been reported. Symptoms typically include dyspnoea, cough (especially a dry nonproductive cough), thoracic pain and fever for which patients should be monitored at each follow-up visit. Patients should be informed of the risk of pneumonitis and advised to contact their doctor immediately should they develop persistent cough or dyspnoea. In addition, pulmonary alveolar haemorrhage has been reported with methotrexate used in rheumatologic and related indications. This event may also be associated with vasculitis and other comorbidities. Prompt investigations should be considered when pulmonary alveolar haemorrhage is suspected to confirm the diagnosis.

4.8. Undesirable effects Respiratory, thoracic and mediastinal disorders Not known: Epistaxis, Pulmonary alveolar haemorrhage* *(has been reported for methotrexate used in rheumatologic and related indications) New product information wording – Extracts from PRAC recommendations on signals EMA/PRAC/8436/2018

Page 3/5

Package leaflet 2. What you need to know before you take [MTX] Warnings and precautions Acute bleeding from the lungs in patients with underlying rheumatologic disease has been reported with methotrexate. If you experience symptoms of spitting or coughing up blood you should contact your doctor immediately.

4. Possible side effects Serious side effects If you develop any of the following side effects, contact your doctor immediately: - inflammation of the lungs (symptoms may be general illness, dry, irritating cough, shortness of breath, breathlessness at rest, chest pain, or fever) - spitting or coughing blood* *(has been reported for methotrexate used in patients with underlying rheumatologic disease)

The following side effects have also been reported: Frequency not known (cannot be estimated from the available data): bleeding from the lungs* *(has been reported for methotrexate used in patients with underlying rheumatologic disease).

3. Pemetrexed – Nephrogenic diabetes insipidus (EPITT no 18930) Summary of product characteristics 4.4. Special warnings and precautions for use Serious renal events, including acute renal failure, have been reported with pemetrexed alone or in association with other chemotherapeutic agents. Many of the patients in whom these occurred had underlying risk factors for the development of renal events including dehydration or pre-existing hypertension or diabetes. Nephrogenic diabetes insipidus and renal tubular necrosis were also reported in post marketing setting with pemetrexed alone or with other chemotherapeutic agents. Most of these events resolved after pemetrexed withdrawal. Patients should be regularly monitored for acute tubular necrosis, decreased renal function and signs and symptoms of nephrogenic diabetes insipidus (e.g. hypernatraemia).

4.8. Undesirable effects Uncommon cases of acute renal failure have been reported with pemetrexed alone or in association with other chemotherapeutic agents (see section 4.4). Nephrogenic diabetes insipidus and renal tubular necrosis have been reported in post marketing setting with an unknown frequency.

New product information wording – Extracts from PRAC recommendations on signals EMA/PRAC/8436/2018

Page 4/5

Package leaflet 4. Possible side effects Not known: frequency cannot be estimated from the available data Increased urine output Thirst and increased water consumption Hypernatraemia – increased sodium in blood

New product information wording – Extracts from PRAC recommendations on signals EMA/PRAC/8436/2018

Page 5/5

New product information wording - Extracts from PRAC ...

Jan 25, 2018 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European ... The product information wording in this document is extracted from the document entitled 'PRAC ... information update, as well as some general guidance on the handling of signals. It can be found ...

97KB Sizes 0 Downloads 207 Views

Recommend Documents

New product information wording - Extracts from PRAC ...
Jan 26, 2017 - Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5525 ... New product information wording – Extracts from PRAC ... System Organ.

New product information wording - European Medicines Agency
Jul 20, 2017 - New product information wording – Extracts from PRAC .... in the fertile age and patients with reduced cerebral compliance (e.g. meningitis,.

New product information wording - European Medicines Agency
Jun 23, 2016 - Summary of product characteristics. Section 4.3 – Contraindications. - Patients with pulmonary hypertension associated with idiopathic ...

New product information wording - European Medicines Agency
Apr 21, 2017 - It can be found here. (in English only). New text to be added to the product information is underlined. Current text to be deleted is struck through ...

New product information wording - European Medicines Agency
May 26, 2016 - Send a question via our website www.ema.europa.eu/contact ... calciphylaxis that can start with a painful skin rash but can lead to other serious ...

New product information wording - European Medicines Agency
Jun 23, 2016 - The product information wording in this document is extracted from the document entitled 'PRAC recommendations on signals' which contains ...

New product information wording - European Medicines Agency
Dec 14, 2017 - The product information wording in this document is extracted from the document entitled 'PRAC recommendations on signals' which contains the whole text of the PRAC recommendations for product information update, as well as some genera

New product information wording - European Medicines Agency
Oct 13, 2016 - Send a question via our website www.ema.europa.eu/contact ... Always take this medicine exactly as your doctor or pharmacist has told you. .... Tell your doctor immediately and stop taking metronidazole if you develop:.

New product information wording - European Medicines Agency
Oct 12, 2017 - Send a question via our website www.ema.europa.eu/contact. © European .... of sensation, memory loss or confusion. These may all be ...

New product information wording - European Medicines Agency
Sep 15, 2016 - Send a question via our website www.ema.europa.eu/contact ... As liver function may change during treatment with {product name}, a close monitoring of ... may need to increase the frequency of your blood tests to check how ...

New product information wording - March 2017 - EN
Mar 23, 2017 - Send a question via our website www.ema.europa.eu/contact. © European ... Package leaflet. 2 - What you need to know before you take ... Before you get KEYTRUDA, tell your doctor if you: - have liver ...

New product information wording - European Medicines Agency
Jun 22, 2017 - Send a question via our website www.ema.europa.eu/contact. © European ... What you need to know before you take . Warnings ...

New product information wording - European Medicines Agency
Jul 21, 2016 - Send a question via our website www.ema.europa.eu/contact ... frequency of these reactions is considered not known (cannot be estimated from the available data) ... 2 - What you need to know before you take [Product name].

Product Information
CAS registry number: [159979-96-1]. Structure: Molar Mass: 151.14. Formula: C7H6FN3. Description: Colourless oil. Purity: ≥95%. Certificates: CoA, 1H, 13C, 19F NMR. CA index names: Benzene, 1-(azidomethyl)-4-fluoro-. Other names: 1. 1-(Azidomethyl)

Extracts from East Africa Trip Journal Ashraf Sayed -
Oct 5, 2005 - not sure if schools were open, many kids live in what seems like poverty ..... some diesel in vain & decided to get back to camp where I had a chicken braai. .... Eventually the auto electrician managed to repair the problem, ...

Extracts from UHJ Climate Change Letter - 29 Nov 2017.pdf ...
and wrangling and the truth will remain hidden.” Also relevant to such participation is greater appreciation and application of Bahá'u'lláh's. insights on moderation. “In all matters moderation is desirable,” He states. “If a thing is carri

Extracts from East Africa Trip Journal Ashraf Sayed -
Oct 5, 2005 - Almost every (if not every) little town had a school & a church. ..... Eventually the auto electrician managed to repair the problem, which .... painful to separate a positive attitude from a non-compliant body. ...... of a coat of pain

Product/ Service Information
Product/. Service. Information. Primary Business Address. Your Address Line 2. Your Address Line 3. Your Address Line 4. Your business tag line here. Franklin Universit,(1902). TAKE ACTION. Franklin University. (614) 797-4700. Toll free 1-877-341-630

Extracts from the AC and ADA regarding the Lectionary.pdf ...
Page 2 of 40. Introduction. On June 18, 1959, the President of the Antepreparatory Commission for the Second Vatican. Council, Domenico Cardinal Tardini, sent a letter to all Cardinals, Archbishops, Bishops. (residential and titular), Superiors Gener

[Ebook] Product Mastery: From Good to Great Product ...
... Product Mastery explores the traits of the best product owners I know offering ... Sutherland Kindle Edition CDN 41 94 Start by marking “ Product Mastery ...